Diagnostic tools company Prescient Medicine Holdings Inc disclosed on Tuesday the completion of the acquisition of AutoGenomics Inc for an undisclosed amount.
Based in the US, AutoGenomics Inc is a molecular diagnostics company that has developed and commercialised the INFINITI platform, a 510(k) exempt, automated, microarray-based multiplexing diagnostic system for personalised medicine, pain management, cardiovascular health, mental health, women's health, oncology, infectious diseases and genetic disorders.
Following the acquisition of AutoGenomics, Prescient Medicine will now advance the development and commercialisation of the INFINITI Neural Response Panel, a novel diagnostic test for the identification of patients who may be at risk for opioid use disorder (OUD), through the US FDA's de Novo premarket submission.
In conjunction with the acquisition, Prescient Medicine will market the INFINITI Neural Response Panel as LifeKit Predict to provide physicians with objective information to help assess the risk of developing an addiction to oral opioids.
The acquisition provides Prescient Medicine with access to the entire INFINITI product portfolio including the suite of INFINITI analyzers and a menu of over 65 molecular diagnostic tests across critical disease indications, which will complement Prescient Medicine's LifeKit product line of diagnostics.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer